A study of the formulation of steroidal suspensions
Short, M.P.; Rhodes, C.T.
Journal of Pharmacy and Pharmacology 24(Suppl): 179p
1972
ISSN/ISBN: 0022-3573 PMID: 4144912 Document Number: 56946
Document emailed within 1 workday
Related Documents
Svirskis, D.; Lin, S.-W.; Brown, H.; Sangaroomthong, A.; Shin, D.; Wang, Z.; Xu, H.; Dean, R.; Vareed, P.; Jensen, M.; Wu, Z. 2018: The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions International Journal of Pharmaceutical Compounding 22(2): 164-171Scheidel, B.; Blume, H.; Walter, K.; von Nieciecki, A.; Babej-Dölle, R.M. 1993: Biological availability of gastric juice-resistant coated diclofenac preparations. 1. Bioavailability study following a single administration of a multiple-unit formulation in comparison with a single-unit formulation Arzneimittel-Forschung 43(11): 1211-1215
Jawade, R.S.; Manekar, A.P.; Senad, D.G.; Bhiwgade, D.A. 1991: Hormonal control of mucosubstances in cervix of female bat rousettus leschenaulti after steroidal and non steroidal treatment Journal of Advanced Zoology 12(2): 81-87
Weissmann, G. 1979: Different effects of steroidal and non-steroidal anti-inflammatory agents on inflammation Reumatizam 26(6): 207-214
Vinogradov, A.P. 1990: PH-metric study of ion equilibrium in erythrocyte suspensions exposed to heat Laboratornoe Delo 11: 17-19
Guillosson, J.J.; David, B.; Laurent, M.; Piette, M. 1982: Comparative study of heparin and histamine release by mast cells using lipid suspensions Annales Pharmaceutiques Francaises 40(1): 11-18
2002: Tobramycin for nebulisation: new formulation. A high price for a small improvement in formulation Prescrire International 11(62): 177-178
2003: Sublingual selegiline: new formulation. New formulation: new risk of oral adverse effects Prescrire International 12(67): 179
Wang, Y.J.; Leesman, G.D.; Lipstein, M.E.; Basch, H.I.; Monkhouse, D.C. 1984: Optimization of autoclave cycles and selection of formulation for parenteral products, Part III: Effect of formulation variables on sporicidal kinetics Journal of parenteral science and technology: a publication of the Parenteral Drug Association 38(2): 78-82
Soni, S.D.; Tench, D.; Ashwood, T.J.; Movin, G. 1990: Pharmacokinetics of an oral controlled release formulation of remoxipride: a double-blind, crossover comparison with conventional formulation in chronic schizophrenics Acta Psychiatrica Scandinavica. Supplementum 358: 45-47
Polukhina, L.M.; Padeĭskaia, E.N.; Kuprina, N.A. 1973: Study of the concentration and chemotherapeutic activity of sulfadimethoxine during experimental oral administration to mice in the form of microcrystalline suspensions Farmakologiia i Toksikologiia 36(1): 64-67
2003: Paracetamol for injection: new formulation. New formulation: why so widely used? Prescrire International 12(67): 178
Jombík, J.; Nemcíková, A.; Schiller, P. 1970: Study of stability of dispersive systems by means of backscattering of beta radiation. I. Suspensions of inorganic components of hydrophilic character in water Ceskoslovenska Farmacie 19(6): 222-224
Vens-Cappell, B.; Hilgenstock, C.; Gellert, M.; Kühle, K.; Reifferscheid, I.; Winckler, P.; Bührens, K.G. 1993: Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 1. Single-dose administration Arzneimittel-Forschung 43(3): 346-350
Jehl, F.; Klossek, J.M.; Peynegre, R.; Serrano, E.; Castillo, L.; Bobin, S.; Desprez, D.; Renault, C.; Neel, V.; Rouffiac, E.; Borie, C. 2002: Sinusal penetration of amoxicillin-clavulanic acid. Formulation 1 g./125 mg., twice daily versus formulation 500 mg./125 mg., three times daily Presse Medicale 31(34): 1596-1603
Bianco, A.C.; Nunes, M.T.; Marone, M.M.; Scalissi, N.M.; Correa, P.H.; Douglas, C.R. 1984: Thyroxine (T4) to 3,5,3'-triiodothyronine (T3) and 3,3',5'-triiodothyronine (reverse T3) conversion in human leukocyte suspensions. Study in hyper and hypothyroidism states Revista Paulista de Medicina 102(2): 61-64
Eckenberger, P.; Bisler, H.; Panse, P. 1993: Transcutaneous absorption of non-steroidal antirheumatics. Clinical study under a new model for investigation of pharmacokinetics Arzneimittel-Forschung 43(4): 469-474
Delacourte-Thibaut, A.; Devise, B.; Guyot, J.C.; Traisnel, M. 1974: Formulation of tablets with the aid of chain extentiometry. I. Technics of the study Journal de Pharmacie de Belgique 29(3): 251-280
Lonauer, G.; Wagner, H.; Boerngen, U.; Goebel, K.M. 1981: Lonazolac-Ca-a non-steroidal antirheumatic agent. Long-term clinical study in chronic polyarthritis Zeitschrift für Rheumatologie 40(4): 161-164
Nishiwaki, K. 1987: Primary gastric lymphoma: clinicopathological study of 27 cases using the Lymphoma Study Group (LSG) classification, Working Formulation for Clinical Usage (WFCU) and Lukes-Collins classifications Nihon Geka Hokan. Archiv für Japanische Chirurgie 56(1): 17-33